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  Twenty－seven cases of reactivated prostatic cancer between 1979 and 1990 were investigated．
Reactivation took place in the form of local aggravation in 3 cases， occurrence or aggravation of
metastasis to bones in 8 cases， and in both forrns in 16 cases．
  The elevation of tumor markers preceded the clinical findings in 11 cases （41％）． ln 75％ of
the cases with occurrence or aggravation of’ metastasis， the elevation of tumor markers preceded
the cllnical findings． This showed that tumor markers were useful in most cases for early detection
of rgactlvation． Howeveらin 3 cases with local aggraVation， the clinical findings preceded the
eleSJatibn of tUmor’ markes． Therefore， it is also important to check the clinical findings at the
follow－up・
  At the time of reactivation， positive rates of prostatic aci．d phosphatase （PAP）， r－seminoprotein
（x－Sm） and prostatic specific antigen （PA） were 78％， 83％ and 80％， respectively． Thus r－Sm and
PA appeared to be more reliable than PAP for monitoring of prostatic cancer．
                                （Acta Urol． Jpn． 37： 39・一43， 1991）

































4e 泌尿紀要 37巻 1号 1991年
Table 1．初診時stageと病理組織分化度
 病理組織



















































計 3（11｝ 8（30） 16 （59｝ 27 （100）
結 果
 1）再燃例の初診時stage6）および病理組織分化度7）：



















































     再燃様式
           局所再燃時，
最初に出現した所見
全身 局所＋全身 計
腫瘍マーカー上昇1｝ o 6 5 11 （41）
腫瘍マーカー上昇
   十
臨床症状，局所増悪
ないし骨転移巣増悪2）
o 1 10 11 （41｝
臨床症状ないし局所増悪 3 1 1 5 ｛19）
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計  14 2 6 5 O 27“ 22 （81）“ L5“9） 一
＊内分泌療法前
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